CB2 and TRPV1 receptors oppositely modulate in vitro human osteoblast activity

Pharmacological Research

Volumn 99, Issue , 2015, Pages 194-201

  Rossi, Francesca ^a   Bellini, Giulia ^a   Tortora, Chiara ^a   Bernardo, Maria Ester ^b   Luongo, Livio ^a   Conforti, Antonella ^b   Starc, Nadia ^b   Manzo, Iolanda ^a   Nobili, Bruno ^a   Locatelli, Franco ^b   Maione, Sabatino ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

CB2 receptor; Endocannabinoid endovanilloid system; Human osteoblast culture; Osteoblast activity markers; TRPV1 receptor

Indexed keywords

ALKALINE PHOSPHATASE; CANNABINOID 2 RECEPTOR; COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR RUNX2; VANILLOID RECEPTOR 1; ENDOCANNABINOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRPV1 RECEPTOR; VANILLOID RECEPTOR;

ARTICLE; BONE MARROW; CELL ACTIVITY; CELL ASSAY; CELL FUNCTION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; MOLECULAR DYNAMICS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; BONE; BONE DEVELOPMENT; CELL CULTURE; CELL DIFFERENTIATION; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY;

BONE AND BONES; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; ENDOCANNABINOIDS; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MESENCHYMAL STROMAL CELLS; NF-KAPPA B; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; OSTEOPOROSIS; OSTEOPROTEGERIN; RECEPTOR, CANNABINOID, CB2; TRPV CATION CHANNELS;

EID: 84937541381     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.06.010     Document Type: Article

References (45)

1. E.F. Eriksen Cellular mechanisms of bone remodeling Rev. Endocr. Metab. Disord. 1 2010 219 227
2. T.L. Andersen, T.E. Sondergaard, K.E. Skorzynska, F. Dagnaes-Hansen, T.L. Plesner, E.M. Hauge, and et al. A physical mechanism for coupling bone resorption and formation in adult human bone Am. J. Pathol. 174 2009 239 247
3. J.E. Aubin Regulation of osteoblast formation and function Rev. Endocr. Metab. Disord. 2 2001 81 94
4. P.J. Marie, and M. Kassem Osteoblasts in osteoporosis: past, emerging, and future anabolic targets Eur. J. Endocrinol. 165 2011 1 10
5. M.F. Pittenger, A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, and et al. Multilineage potential of adult human mesenchymal stem cells Science 284 1999 143 147
6. M.E. Bernardo, F. Locatelli, and W.E. Fibbe Mesenchymal stromal cells Ann. N. Y. Acad. Sci. 1176 2009 101 117
7. M.E. Bernardo, A.M. Cometa, D. Pagliara, L. Vinti, F. Rossi, R. Cristantielli, and et al. Ex vivo expansion of mesenchymal stromal cells Best Pract. Res. Clin. Haematol. 24 2011 73 81
8. B. Sacchetti, A. Funari, S. Michienzi, S. Di Cesare, S. Piersanti, I. Saggio, and et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment Cell 131 2007 324 336
9. T. Gaur, C.J. Lengner, H. Hovhannisyan, R.A. Bhat, P.V. Bodine, B.S. Komm, and et al. Canonical WNT signaling promotes osteogenesis by directly stimulating Runx2 gene expression J. Biol. Chem. 280 2005 33132 33140
10. B. Clarke Normal bone anatomy physiology Clin. J. Am. Soc. Nephrol. Suppl. 3 2008 S131 S139
11. B. Brodsky, and A.V. Persikov Molecular structure of the collagen triple helix Adv. Protein Chem. 70 2005 301 339
12. S. Palumbo, and W.J. Li Osteoprotegerin enhances osteogenesis of human mesenchymal stem cells Tissue Eng. A 19 2013 2176 2187
13. N. Udagawa, N. Takahashi, H. Yasuda, A. Mizuno, K. Itoh, Y. Ueno, and et al. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function Endocrinology 141 2000 3478 3484
14. D.L. Lacey, E. Timms, T.L. Tan, M.J. Kelley, C.R. Dunstan, T. Burgess, and et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 1998 165 176
15. T. Suda, N. Takahashi, N. Udagawa, E. Jimi, M.T. Gillespie, and T.J. Martin Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families Endocr. Rev. 20 1999 345 357
16. L.C. Hofbauer, S. Khosla, C.R. Dunstan, D.L. Lacey, W.J. Boyle, and B.L. Riggs The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption J. Bone Miner. Res. 15 2000 2 12
17. H. Hsu, D.L. Lacey, C.R. Dunstan, I. Solovyev, A. Colombero, E. Timms, and et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand Proc. Natl. Acad. Sci. U. S. A. 96 1999 3540 3545
18. T.D. Rachner, S. Khosla, and L.C. Hofbauer Osteoporosis: now and the future Lancet 377 2011 1276 1287
19. R. Bernabei, A.M. Martone, E. Ortolani, F. Landi, and E. Marzetti Screening, diagnosis and treatment of osteoporosis: a brief review Clin. Cases Miner. Bone Metab. 11 2014 201 207
20. N. Di Daniele, M.G. Carbonelli, N. Candeloro, L. Iacopino, A. De Lorenzo, and A. Andreoli Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women: a double-blind, randomized, controlled trial Pharmacol. Res. 50 2004 637 641
21. Y. Zhang, A.D. Bradley, D. Wang, and R.A. Reinhardt Statins, bone metabolism and treatment of bone catabolic diseases Pharmacol. Res. 88 2014 53 61
22. J.B. Payne, and L.M. Golub Using tetracyclines to treat osteoporotic/osteopenic bone loss: from the basic science laboratory to the clinic Pharmacol. Res. 63 2011 121 129
23. S.U. Lee, S.J. Park, H.B. Kwak, J. Oh, Y.K. Min, and S.H. Kim Anabolic activity of ursolic acid in bone: stimulating osteoblast differentiation in vitro and inducing new bone formation in vivo Pharmacol. Res. 58 2008 290 296
24. I. Bab, O. Ofek, J. Tam, J. Rehnelt, and A. Zimmer Endocannabinoids and the regulation of bone metabolism J. Neuroendocrinol. 20 2008 69 74
25. I. Bab, and A. Zimmer Cannabinoid receptors and the regulation of bone mass Br. J. Pharmacol. 153 2008 182 188
26. I. Bab, A. Zimmer, and E. Melamed Cannabinoids and the skeleton: from marijuana to reversal of bone loss Ann. Med. 41 2009 560 567
27. 2, regulates bone mass Proc. Natl. Acad. Sci. U. S. A. 103 2006 696 701
28. M. Bifulco The endocannabinoid system: from biology to therapy Pharmacol. Res. 60 2009 75 76
29. V. Di Marzo The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation Pharmacol. Res. 60 2009 77 84
30. L. Fattore, P. Fadda, and W. Fratta Endocannabinoid regulation of relapse mechanisms Pharmacol. Res. 56 2007 418 427
31. F. Rossi, D. Siniscalco, L. Luongo, L. De Petrocellis, G. Bellini, S. Petrosino, and et al. The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption Bone 44 2009 476 484
32. F. Rossi, G. Bellini, L. Luongo, M. Torella, S. Mancusi, L. De Petrocellis, and et al. The endovanilloid/endocannabinoid system: a new potential target for osteoporosis therapy Bone 48 2011 997 1007
33. 1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice Br. J. Pharmacol. 171 2014 2621 2630
34. 2 receptor expression Pharmacol. Res. 68 2013 7 15
35. R. Pandey, K. Mousawy, M. Nagarkatti, and P. Nagarkatti Endocannabinoids and immune regulation Pharmacol. Res. 60 2009 85 92
36. F. Rossi, G. Bellini, C. Tolone, L. Luongo, S. Mancusi, A. Papparella, and et al. The cannabinoid receptor type 2 Q63R variant increases the risk of celiac disease: implication for a novel molecular biomarker and future therapeutic intervention Pharmacol. Res. 66 2012 88 94
37. I. Bab, R. Smoum, H. Bradshaw, and R. Mechoulam Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family Br. J. Pharmacol. 163 2011 1441 1446
38. A.I. Idris Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies Curr. Neuropharmacol. 8 2010 243 253
39. A.I. Idris, R.J. van't Hof, I.R. Greig, S.A. Ridge, D. Baker, R.A. Ross, and et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors Nat. Med. 11 2005 774 779
40. A.I. Idris, A. Sophocleous, E. Landao-Bassonga, R.J. van't Hof, and S.H. Ralston Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor Endocrinology 149 2008 5619 5626
41. A.I. Idris, A. Sophocleous, E. Landao-Bassonga, M. Canals, G. Milligan, D. Baker, and et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells Cell Metab. 10 2009 139 147
42. 1 ion channel antagonist capsazepine inhibits osteoclast and osteoblast differentiation in vitro and ovariectomy induced bone loss in vivo Bone 46 2010 1089 1099
43. 2 receptors Calcif. Tissue Int. 80 2007 50 59
44. 1) channels Haematologica 99 2014 1876 1884
45. 1: 10 years from channel cloning to antagonist proof-of-concept Nat. Rev. Drug Dis. 6 2007 357 372